Alembic gets FDA OK for generic Vesicare
Alembic has received the Food and Drug Administration’s approval for solifenacin succinate tablets, in 5-mg and 10-mg dosage strengths.
The product is indicated for the treatment of overactive bladder.
It is the generic of Astellas Pharma’s Vesicare tablets.
Solifenacin succinate tablets 5 mg and 10 mg had a market value of approximately $967 million for the 12 months ending December 2018, according to IQVIA.
The product is indicated for the treatment of overactive bladder.
It is the generic of Astellas Pharma’s Vesicare tablets.
Solifenacin succinate tablets 5 mg and 10 mg had a market value of approximately $967 million for the 12 months ending December 2018, according to IQVIA.
